Mylan Laboratories Ltd. - Research Center
MATRIXLAB Group (B) BSE data
Add to watchlist
| Results |
Half yearly
|
| Statement | |
| More |
Half yearly results in brief
(Rs crore)
| Mar ' 09 | Sep ' 08 | Mar ' 08 | Sep ' 07 | Mar ' 07 | |
|---|---|---|---|---|---|
| Sales | 842.34 | 659.80 | 559.44 | 427.99 | 412.85 |
| Operating profit | 189.62 | 138.00 | 119.21 | 66.89 | 64.94 |
| Interest | 32.96 | 23.96 | 16.41 | 10.36 | 8.74 |
| Gross profit | 167.50 | 125.05 | 102.70 | 68.14 | 78.25 |
| EPS (Rs) | 6.92 | 5.31 | -21.85 | 2.55 | 3.96 |
Half yearly
results in details
| Mar ' 09 | Sep ' 08 | Mar ' 08 | Sep ' 07 | Mar ' 07 | |
|---|---|---|---|---|---|
| Other income | 10.84 | 11.01 | -0.10 | 11.61 | 22.05 |
| Stock adjustment | -5.70 | -60.93 | -59.36 | -13.22 | -35.80 |
| Raw material | 400.57 | 347.43 | 311.95 | 221.68 | 230.49 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 51.18 | 45.83 | 35.91 | 34.47 | 31.15 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | 87.97 | 89.68 | 61.29 | 45.12 | 49.72 |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 118.70 | 99.79 | 90.44 | 73.05 | 72.36 |
| Provisions made | - | - | - | - | - |
| Depreciation | 18.59 | 16.99 | 14.95 | 14.59 | 12.99 |
| Taxation | 41.99 | 26.03 | 24.35 | 14.12 | 4.23 |
| Net profit / loss | 106.92 | 82.03 | -337.79 | 39.43 | 61.03 |
| Extra ordinary item | - | - | -401.18 | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 30.92 | 30.92 | 30.92 | 30.90 | 30.82 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | 369.11 | 369.03 | 368.77 | 367.83 | 364.06 |
| Agg.of non promotoholding (%) | 23.87 | 23.87 | 23.85 | 23.81 | 23.62 |
| OPM (%) | 22.51 | 20.92 | 21.31 | 15.63 | 15.73 |
| GPM (%) | 19.63 | 18.64 | 18.36 | 15.50 | 17.99 |
| NPM (%) | 12.53 | 12.23 | -60.39 | 8.97 | 14.03 |
© 2025 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis